, Volume 77, Issue 18, pp 2003–2012 | Cite as

Nonacog Beta Pegol: A Review in Haemophilia B

Adis Drug Evaluation


Nonacog beta pegol [Refixia® (EU)] is an intravenously-administered, glycoPEGylated recombinant factor IX (FIX), with an extended terminal half-life. It is approved in the EU for the treatment and prophylaxis of bleeding in patients aged ≥ 12 years with haemophilia B. The therapeutic efficacy and safety of nonacog beta pegol was demonstrated in the phase 3 Paradigm trials in previously treated adolescents and adults with haemophilia B. In Paradigm 2, nonacog beta pegol showed good haemostatic effects when treating bleeds on-demand, and reduced annualized bleeding rates when used as a once-weekly prophylaxis. It also improved some health-related quality of life measures in adult patients. The longer-term efficacy of nonacog beta pegol was demonstrated in the open-label extension Paradigm 4 trial. In Paradigm 3, nonacog beta pegol effectively maintained intraoperative and postoperative haemostasis. Nonacog beta pegol was well tolerated in phase 3 clinical trials in patients with haemophilia B, with no evidence of FIX inhibitor formation, allergic reactions or thromboembolic complications. In conclusion, nonacog beta pegol is effective and well tolerated in the on-demand, prophylaxis and perioperative settings in adolescent and adults with haemophilia B. Its extended half-life allows for once-weekly prophylaxis. Therefore, nonacog beta pegol is a useful additional treatment option for patients with haemophilia B.



During the peer review process, the manufacturer of nonacog beta pegol was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards


The preparation of this review was not supported by any external funding.

Conflict of interest

Yahiya Syed is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/72FBF0602C81013B.


  1. 1.
    Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia 2nd edition. 2013. http://www.wfh.org. Accessed 14 Aug 2017.
  2. 2.
    White GC II, Rosendaal F, Aldedort LM, et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85(3):560.PubMedGoogle Scholar
  3. 3.
    Nazeef M, Sheehan JP. New developments in the management of moderate-to-severe hemophilia B. J Blood Med. 2016;7:27–38.PubMedPubMedCentralGoogle Scholar
  4. 4.
    O’Hara J, Hughes D, Camp C, et al. The cost of severe haemophilia in Europe: the CHESS study. Orphanet J Rare Dis. 2017;12(1):106.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Peyvandi F, Garagiola I, Biguzzi E. Advances in the treatment of bleeding disorders. J Thromb Haemost. 2016;14(11):2095–106.CrossRefPubMedGoogle Scholar
  6. 6.
    Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016;388(10040):187–97.CrossRefPubMedGoogle Scholar
  7. 7.
    Skinner MW. WFH: closing the global gap: achieving optimal care. Haemophilia. 2012;18(Suppl. 4):1–12.CrossRefPubMedGoogle Scholar
  8. 8.
    Collins PW, Young G, Knobe K, et al. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood. 2014;124(26):3880–6.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Santagostino E, Martinowitz U, Lissitchkov T, et al. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood. 2016;127(14):1761–9.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013;369(24):2313–23.CrossRefPubMedGoogle Scholar
  11. 11.
    Østergaard H, Bjelke JR, Hansen L, et al. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. Blood. 2011;118(8):2333–41.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Nonacog beta pegol (Refixia®): summary of product characteristics. 2017. http://www.ema.europa.eu. Accessed 14 Aug 2017.
  13. 13.
    Negrier C, Knobe K, Tiede A, et al. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood. 2011;118(10):2695–701.CrossRefPubMedGoogle Scholar
  14. 14.
    Escobar MA, Tehranchi R, Karim FA, et al. Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX. Haemophilia. 2017;23(1):67–76.CrossRefPubMedGoogle Scholar
  15. 15.
    Young G, Collins PW, Colberg T, et al. Nonacog beta pegol (N9-GP) in haemophilia B: a multinational phase III safety and efficacy extension trial (Paradigm 4). Thromb Res. 2016;141:69–76.CrossRefPubMedGoogle Scholar
  16. 16.
    Tiede A, Abdul-Karim F, Carcao M, et al. Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials. Haemophilia. 2017;23(4):547–55.CrossRefPubMedGoogle Scholar
  17. 17.
    Collins PW, Moss J, Knobe K, et al. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX. J Thromb Haemost. 2012;10(11):2305–12.CrossRefPubMedGoogle Scholar
  18. 18.
    Rebinyn® (Coagulation Factor IX (Recombinant), GlycoPEGylated) lyophilized powder for solution for intravenous injection: US prescribing information. 2017. https://www.fda.gov. Accessed 11 Sept 2017.
  19. 19.
    Carcao M, Zak M, Abdul Karim F, et al. Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial. J Thromb Haemost. 2016;14(8):1521–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Negrier C, Young G, Abdul Karim F, et al. Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials. Haemophilia. 2016;22(4):507–13.CrossRefPubMedGoogle Scholar
  21. 21.
    Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12(11):1935–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Chowdary P, Kearney S, Regnault A, et al. Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product. Haemophilia. 2016;22(4):e267–74.CrossRefPubMedGoogle Scholar
  23. 23.
    Rosen P, Rosen S, Ezban M, et al. Overestimation of N-glycoPEGylated factor IX activity in a one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX. J Thromb Haemost. 2016;14(7):1420–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Colvin BT, Astermark J, Fischer K, et al. European principles of haemophilia care. Haemophilia. 2008;14(2):361–74.CrossRefPubMedGoogle Scholar
  25. 25.
    Makris M. Prophylaxis in haemophilia should be life-long. Blood Transfus. 2012;10(2):165–8.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Sorensen B, Auerswald G, Benson G, et al. Rationale for individualizing haemophilia care. Blood Coagul Fibrinolysis. 2015;26(8):849–57.CrossRefPubMedGoogle Scholar
  27. 27.
    Baumann A, Tuerck D, Prabhu S, et al. Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis? Drug Discov Today. 2014;19(10):1623–31.CrossRefPubMedGoogle Scholar
  28. 28.
    Sternebring O, Christensen JK, Bjornsdottir I. Pharmacokinetics, tissue distribution, excretion, and metabolite profiling of PEGylated rFIX (nonacog beta pegol, N9-GP) in rats. Eur J Pharm Sci. 2016;92:163–72.CrossRefPubMedGoogle Scholar
  29. 29.
    Webster R, Elliott V, Park BK, et al. PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals. In: Veronese FM, editor. PEGylated protein drugs: basic science and clinical applications. Basel: Birkhäuser Basel; 2009. p. 127–46.CrossRefGoogle Scholar
  30. 30.
    Lyseng-Williamson KA. Coagulation factor IX (recombinant), albumin fusion protein (albutrepenonacog alfa; Idelvion®): a review of its use in haemophilia B. Drugs. 2017;77(1):97–106.CrossRefPubMedGoogle Scholar
  31. 31.
    Hoy SM. Eftrenonacog alfa: a review in haemophilia B. Drugs. 2017;77(11):1235–46.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2017

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations